Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC200 in Osteoarthritic Knee Pain
NCT06614608Phase 1Not yet recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CGS-200-5 in osteoarthritis (OA) (2 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoint: Incidence of adverse events (AEs) at 34 days. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
CGS-200-5
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06614608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614608.